Correlation between glycated hemoglobin and mean plasma glucose in hemodialysis patients

Israel, Ezra; Geara, Abdallah S.; Maarouf, Omar H.; Ayoub, Isabelle; Rached, Jacques Abi; Rizk, Sanaa; Staynberg, Norbert; Samarneh, Majed; El‐Sayegh, Suzanne

doi:10.1007/s11255-010-9800-1

Cited by 3 publications

(5 citation statements)

References 12 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Levels of glycated albumin were similar between the two groups (23.0% ± 7.1% vs. 21.8% ± 7.8%, P = NS) 23 . This finding has been reproduced in other studies and indicates that patients treated with ESA have decreased HbA1c levels independent of plasma glucose 24–26 …”

Section: Discussionsupporting

confidence: 68%

“…23 This finding has been reproduced in other studies and indicates that patients treated with ESA have decreased HbA1c levels independent of plasma glucose. [24][25][26] A secondary aim of this study was to investigate markers that could account for alterations in the erythrocyte lifespan. Haptoglobin and LDH are well-known markers of hemolysis, and we expected that increased erythrocyte destruction would be associated with erythrocyte lifespan.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Reduced erythrocyte lifespan measured by chromium‐51 in patients with type 2 diabetes undergoing long‐term hemodialysis

Bomholt

Oturai

Rix

et al. 2020

Hemodialysis International

View full text Add to dashboard Cite

Introduction: A reduced erythrocyte lifespan potentially explains the low hemoglobin A1c values found in hemodialysis patients. However, data supporting this notion in patients with type 2 diabetes is unclear. We evaluated the erythrocyte lifespan in patients with type 2 diabetes undergoing long-term hemodialysis and investigated potential predictors of erythrocyte lifespan.Methods: Long-term hemodialysis patients with type 2 diabetes and type 2 diabetes patients without nephropathy (estimated glomerular filtration rate > 60 mL/min/1.73 m 2 ) were included. The erythrocyte lifespan was measured using chromium-51 ( 51 Cr)-labeled erythrocytes. Blood radiotracer activity was measured six to nine times over a period of 3-5 weeks to determine the erythrocyte lifespan of each patient. Biochemical markers were obtained five times over 16 weeks and associated with the erythrocyte lifespan.Findings: Type 2 diabetes patients undergoing hemodialysis (N = 13) had a significantly shorter median erythrocyte lifespan of 49.7 (interquartile range [IQR] = 44.1-58.6) days compared with 64.2 (IQR = 62.6-83.5) days in the control group (N = 10) (P < 0.001) with a difference between medians of 14.5 (95% confidence interval = 8.1-38.8) days. In the hemodialysis group, no association could be detected between the erythrocyte lifespan and markers of hemolysis, level of inflammation, or urea.Discussion: A reduced erythrocyte lifespan was detected in type 2 diabetes patients undergoing long-term hemodialysis. This may contribute to the reduced hemoglobin A1c values observed in the type 2 diabetic hemodialysis population. An association could not be detected between the erythrocyte lifespan and biochemical markers of hemolysis or inflammation.

show abstract

Section: Discussionsupporting

confidence: 68%

Section: Discussionmentioning

confidence: 99%

Reduced erythrocyte lifespan measured by chromium‐51 in patients with type 2 diabetes undergoing long‐term hemodialysis

Bomholt

Oturai

Rix

et al. 2020

Hemodialysis International

View full text Add to dashboard Cite

show abstract

“…Therefore we included even non diabetic patients because blood glucose variability is in the normal range and HbA1c oscillation is more likely induced by ESA doses than abnormal blood glucose. The inverse correlation of HbA1c and dose of ESA was confirmed by our data with the differences of the sequential values [15,23,[42][43][44]], but we were first to show this effect with a new long acting ESA with continuous stimulation. We demonstrate in our study, that a median dose escalation with 10,000 IU per week induces an estimated HbA1c decrease of 0.6 percent.…”

Section: δHb and δHba1csupporting

confidence: 74%

“…In contrary to other studies [23], short term decrease or increase of Hb was avoided in our study in regard of potential adverse cardiovascular events [33,34,[39][40][41]. At first, we here report a comparison of a new long acting ESA and a standard ESA with long experiences with the focus Hb stability, ESA doses and possible influences on HbA1c and fructosamine [23,[42][43][44] and the inclusion of non diabetic patients. Therefore we included even non diabetic patients because blood glucose variability is in the normal range and HbA1c oscillation is more likely induced by ESA doses than abnormal blood glucose.…”

Section: δHb and δHba1cmentioning

confidence: 93%

Influence of Erythropoiesis-Stimulating Agents on HbA1c and Fructosamine in Patients with Haemodialysis

Rasche

Ebert

Beckmann

et al. 2017

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

HbA1c is the most accepted laboratory parameter for the long term observation of glucose control. There is still much of a debate about the use of HbA1c as a metabolic indicator in diabetic patients (DM) on haemodialysis (HD) and erythropoiesis-stimulating agent (ESA) therapy because of the altered erythrocyte turn over in patients with chronic kidney disease and haemodialysis (CKD5D). In 102 CKD5 patients with and without diabetes mellitus, we examined the dose dependent variability in HbA1c and fructosamine levels under haemodialysis and treated with epoetin α (n=48) and a new generation agent with continuous stimulation of methoxy polyethylene glycol epoetin beta (C.E.R.A.; n=54). HbA1c levels were affected by therapy with ESA treatments. ESA dose was inversely correlated with HbA1c and an escalation of 10.000 IU per week induced an estimated decrease of HbA1c of 0.6 percent. In addition, the increase of reticulocyte number as a marker for erythropoiesis was significantly inversely correlated with the increase of ΔHbA1c. ESA treatments had no such effect on the alternative metabolic parameter fructosamine. When compared, both therapeutic agents had comparable success in attaining haemoglobin (Hb) target values. C.E.R.A. showed better correlation and was more effective over a longer dose interval. Our results show that HbA1c levels in patients should be carefully interpreted based on interfering factors. Nevertheless, HbA1c is currently the most consistent parameter for use ascertaining metabolic status of patients suffering from diabetes mellitus.

show abstract

“…Tüm dünyada kronik böbrek yetmezliklerinin en önemli sebepleri arasında DM ilk sırada yer almaktadır [8]. DM'li hemodiyaliz hastalarında her 3 ayda bir yapılan HbA1c testi, hastaların uzun dönem glisemi kontrolünde değerli bir yöntemdir [9].…”

Section: Introductionunclassified

Relationship between Hba1c and blood glucose level in hemodialysis patients with diabetes mellitus

Motor¹,

Dokuyucu²,

Sefil³

et al. 2013

DicleMedj

View full text Add to dashboard Cite

Within in the scope of this study, a researchwas aimed at the relationship between HbA1c markersand blood glucose levels with DM, chronic renal failureand receiving dialysis treatment.Methods: In this study, monthly glucose levels and quarterlyHbA1c markers of 131 patients (53 female, 78 male)receiving dialysis treatment in a private dialysis centerbetween January 1, 2009-July 31, 2010 were evaluatedretrospectively.Results: The average age of 131 cases was 63.3±11.2years (range, 30-91). Gender distribution of the cases: 53female (40.5%), 78 male (59.5%). While the age averageof the females was 62.2±11.2 and the males’ was64.1±11.2. The average glucose level of the females andmales have a correlation to average HbA1c (Female:p<0.001, r=0.761, Males: p<0.001, r=0.743). The averageglucose level of the both case groups have a correlationto average HbA1c (p<0.001, r=0.755). While 32.8%of the examined HbA1c results were observed underthe level 6,5%, and 67.2% of the examined results wereobserved above the level 6.5%. While 18.3% of the preprandialblood glucose levels were obtained under 126mg/dl level, and 81.3% of the results were obtained above126 mg/dl level. It has been observed that the mean bloodglucose level has a correlation to average HbA1c level.Conclusion: The measurement of HbA1c and blood glucose(pre-prandial and postprandial) and the correlationbetween them, by virtue of the fact that, are vitally importantin cardiovascular mortality and morbidity, monitorof DM for the dialysis patients with diabetic nephropathy.Key words: Hemodialysis, diabetes mellitus, HbA1

show abstract

Correlation between glycated hemoglobin and mean plasma glucose in hemodialysis patients

Abstract: The value of HbA1c in hemodialysis for monitoring glycemic control is limited in the setting of a high reticulocyte count (>2%) and a high weekly erythropoietin dose. Checking HbA1c monthly versus every 3 months is not a better approximation of glycemic control in hemodialysis patients.

Cited by 3 publications

References 12 publications

Reduced erythrocyte lifespan measured by chromium‐51 in patients with type 2 diabetes undergoing long‐term hemodialysis

Reduced erythrocyte lifespan measured by chromium‐51 in patients with type 2 diabetes undergoing long‐term hemodialysis

Influence of Erythropoiesis-Stimulating Agents on HbA1c and Fructosamine in Patients with Haemodialysis

Relationship between Hba1c and blood glucose level in hemodialysis patients with diabetes mellitus

Contact Info

Product

Resources

About